Galapagos NV - Product Pipeline Review

Global Markets Direct’s, ‘Galapagos NV - Product Pipeline Review - 2016’, provides an overview of the Galapagos NV’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Galapagos NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Galapagos NV

The report provides overview of Galapagos NV including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Galapagos NV’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Galapagos NV’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Galapagos NV’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Galapagos NV

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Galapagos NV’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Galapagos NV Snapshot 6

Galapagos NV Overview 6

Key Information ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Galapagos NV Snapshot 6

Galapagos NV Overview 6

Key Information 6

Key Facts 6

Galapagos NV - Research and Development Overview 7

Key Therapeutic Areas 7

Galapagos NV - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Galapagos NV - Pipeline Products Glance 17

Galapagos NV - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Galapagos NV - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Galapagos NV - Drug Profiles 21

filgotinib 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

GLPG-1205 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

GLPG-1690 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

GLPG-1837 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

DT-200 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

GLPG-1972 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

GLPG-2222 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

GLPG-2451 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

MOR-106 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

GLPG-1492 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

GLPG-1790 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

GLPG-1837 + GLPG-2222 + GLPG-2665 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

GLPG-2534 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

GLPG-2665 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

GLPG-2737 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

GLPG-2851 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

GLPG-2938 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Galapagos NV - Pipeline Analysis 44

Galapagos NV - Pipeline Products by Target 44

Galapagos NV - Pipeline Products by Route of Administration 45

Galapagos NV - Pipeline Products by Molecule Type 46

Galapagos NV - Pipeline Products by Mechanism of Action 47

Galapagos NV - Recent Pipeline Updates 48

Galapagos NV - Dormant Projects 60

Galapagos NV - Discontinued Pipeline Products 61

Discontinued Pipeline Product Profiles 61

GLPG-0187 61

GLPG-0259 61

GLPG-1179 61

GLPG-1205 61

GLPG-1332 61

GLPG-1577 61

Galapagos NV - Locations And Subsidiaries 62

Head Office 62

Other Locations & Subsidiaries 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

List of Tables

Galapagos NV, Key Information 6

Galapagos NV, Key Facts 6

Galapagos NV - Pipeline by Indication, 2016 8

Galapagos NV - Pipeline ...

List of Tables

Galapagos NV, Key Information 6

Galapagos NV, Key Facts 6

Galapagos NV - Pipeline by Indication, 2016 8

Galapagos NV - Pipeline by Stage of Development, 2016 10

Galapagos NV - Monotherapy Products in Pipeline, 2016 11

Galapagos NV - Combination Treatment Modalities in Pipeline, 2016 12

Galapagos NV - Partnered Products in Pipeline, 2016 13

Galapagos NV - Partnered Products/ Combination Treatment Modalities, 2016 14

Galapagos NV - Out-Licensed Products in Pipeline, 2016 15

Galapagos NV - Out-Licensed Products/ Combination Treatment Modalities, 2016 16

Galapagos NV - Phase II, 2016 17

Galapagos NV - Phase I, 2016 18

Galapagos NV - Preclinical, 2016 19

Galapagos NV - Discovery, 2016 20

Galapagos NV - Pipeline by Target, 2016 44

Galapagos NV - Pipeline by Route of Administration, 2016 45

Galapagos NV - Pipeline by Molecule Type, 2016 46

Galapagos NV - Pipeline Products by Mechanism of Action, 2016 47

Galapagos NV - Recent Pipeline Updates, 2016 48

Galapagos NV - Dormant Developmental Projects,2016 60

Galapagos NV - Discontinued Pipeline Products, 2016 61

Galapagos NV, Subsidiaries 62

List of Figures

List of Figures

Galapagos NV - Pipeline by Top 10 Indication, 2016 8

Galapagos NV - Pipeline by Stage of Development, 2016 10

Galapagos NV ...

List of Figures

Galapagos NV - Pipeline by Top 10 Indication, 2016 8

Galapagos NV - Pipeline by Stage of Development, 2016 10

Galapagos NV - Monotherapy Products in Pipeline, 2016 11

Galapagos NV - Pipeline by Target, 2016 44

Galapagos NV - Pipeline by Route of Administration, 2016 45

Galapagos NV - Pipeline by Molecule Type, 2016 46

Galapagos NV - Pipeline Products by Mechanism of Action, 2016 47

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports